Salute e Benessere

Groupe Casino : Third-quarter 2023 – France

Third-quarter 2023 – FranceSales: France Retail sales were down -5.6% on a same-store basis, reflecting: The effect of price readjustment measures in Supermarkets/Hypermarkets taken in Q1.The commercial turnaround in historic supermarkets is confirmed, with customer traffic and volumes now positive 1at +8% and +3% respectively in 4H, while hypermarkets are seeing a gradual improvement in customer traffic Growth of +0.4% in Parisian and convenience banners, penalized by...
Nasdaq GlobeNewswire
26/10/2023

Essity: Interim Report Quarter 3 2023

Essity delivered strong earnings for the third quarter of 2023. Net sales continued to increase and adjusted EBITA increased by 78% to SEK 5.3bn. The adjusted EBITA margin was higher for the fourth consecutive quarter and amounted to 12.2%. As leading in the growing global hygiene and health market, we are taking further steps toward achieving our Group targets concerning sales growth, return and a reduced environmental footprint. Essity delivered strong earnings for the third quarter of 2023...
PR Newswire
26/10/2023

Roche collaborates with Ibex and Amazon Web Services to accelerate adoption of…

"This exciting collaboration brings powerful AI solutions to pathology labs," said Michael Rivers, Lifecycle Leader for Roche Digital Pathology. "Using the navify Digital Pathology platform pathologists can securely access third-party AI-powered technology alongside Roche's growing menu of AI-based image analysis tools in an efficient clinical workflow." "This exciting collaboration brings powerful AI solutions to pathology labs," saidMichael Rivers, Lifecycle…
PR Newswire
26/10/2023

Pixium Vision announces its financial results for H1 2023 and provides update

Pixium Vision announces its financial results for H1 2023 and provides update Post period event: Received shareholder loan of €3 million from BPIFrance and Sofinnova. Extension of the maturity of outstanding notes €1.25 million, Implemented a reverse stock split, exchanging 50 old to 1 current share, applied for and obtained safeguard proceeding, applied for conversion of the safeguard proceeding to a court-ordered receivership and announced the opening of a process to find a buyer...
Nasdaq GlobeNewswire
26/10/2023

Vivoryon Therapeutics N.V. Provides Comprehensive Progress Report for Ongoing…

Vivoryon Therapeutics N.V. Provides Comprehensive Progress Report for Ongoing Varoglutamstat Clinical Program Following R&D Event and VIVA-MIND DSMB Dose Decision Both VIVIAD and VIVA-MIND progressing at 600mg twice daily with oral administration following two independent positive DSMB decisions Varoglutamstat demonstrates very encouraging safety data with no evidence of drug-related ARIAs at therapeutic dose of 600mg twice daily, a dose demonstrated to result in nearly 90%...
Nasdaq GlobeNewswire
26/10/2023

Ipsen delivers solid sales growth in the first nine months of 2023 and confirms…

Paris (France), 26 October 2023 Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical company, today presents its sales performance for the year to date and the third quarter of 2023. YTD2023YTD2022% changeQ32023Q32022% change€m€mActualCER1€m€mActualCER1 Oncology 1,744.11,767.2...
Nasdaq GlobeNewswire
26/10/2023

Mithra and Searchlight Pharma sign DONESTA® licensing agreement for Canada

Mithra and Searchlight Pharma sign DONESTA ®licensing agreement for CanadaMithra to receive EUR 1.5 million milestone payout as a result of the signing of the agreementAdditional licensing payout of EUR 15.55 million in regulatory and sales milestones, along with tiered royalties on annual net salesSearchlight anticipates filing of Canadian regulatory submission for DONESTA ®as a treatment for the symptoms of menopause in H1 2024...
Nasdaq GlobeNewswire
26/10/2023

Pharming Group reports third quarter 2023 financial results

Pharming Group reports third quarter 2023 financial results Third quarter 2023 revenues increased 23% to US$66.7 million, compared to the third quarter 2022, driven by RUCONEST® revenue and the U.S. commercial launch of Joenja®Nine month year to date 2023 revenues increased 9% to US$164.1million, compared to nine month year to date 2022RUCONEST® revenues increased 11% in the third quarter 2023 to US$60.2 million, compared to the third quarter 2022, and increased 18% compared to...
Nasdaq GlobeNewswire
26/10/2023

New CRISPR/Cas9 Licensing Agreement for ERS Genomics & CHUM Research Centre…

Dr. Emmanuelle Charpentier, founder of ERS Genomics, received the 2020 Nobel Prize for the discovery of CRISPR/Cas9. As a direct outcome, the ERS patent portfolio is the definitive collection of proprietary rights to this gene editing technology. Dr.Emmanuelle Charpentier, founder of ERS Genomics, received the 2020 Nobel Prize for the discovery of CRISPR/Cas9. As a direct outcome, the ERS patent portfolio is the definitive collection of proprietary rights to this gene editing technology...
PR Newswire
26/10/2023

New data from LEQEMBI® (lecanemab-irmb) phase 3 Clarity AD study and…

Eisai is hosting a live webcast of the scientific session featuring the LEQEMBI presentations, which can be viewed on the investors section of the Eisai Co., Ltd. website. The content will be available on demand afterward. Eisai is hosting a live webcast of the scientific session featuring the LEQEMBI presentations, which can be viewed onthe investors section of the Eisai Co., Ltd. website. The content will be available on demand afterward. Eisai serves as the lead of LEQEMBI development...
PR Newswire
26/10/2023

Esoteric Testing Market to Reach $68.5 Billion, Globally, by 2032 at 11.0% CAGR…

Request Sample of the Report on Esoteric Testing Market Forecast 2032- https://www.alliedmarketresearch.com/request-sample/12387 Request Sample of the Report on Esoteric Testing Market Forecast 2032-https://www.alliedmarketresearch.com/request-sample/12387 Esoteric tests refer to specialized laboratory procedures that are not commonly available in typical clinical labs. These tests are conducted in specialized labs due to their complexity, their relevance to rare disorders, or the...
PR Newswire
26/10/2023

High-grade Glioma Market to Witness Upsurge in Growth by 2032, Predicts…

Key Takeaways from the High-grade Glioma Market Report Key Takeaways from the High-grade Glioma Market Report Discover which therapies are expected to grab the major high-grade glioma market share @High-grade Glioma Market Report High-grade Glioma Overview High-grade gliomas, also known as HGG, are aggressive tumors that originate within the central nervous system. They are solid growths that develop from transformed astrocyte cells in either the brain or the spinal cord...
PR Newswire
25/10/2023

Jazz Pharmaceuticals to Report 2023 Third Quarter Financial Results on November…

Interested parties may access the live audio webcast via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. Interested parties may access the live audio webcast via the Investors section of the Jazz Pharmaceuticals website athttps://investor.jazzpharma.com/investors/events-presentations...
PR Newswire
25/10/2023

MDxHealth to Present Third Quarter 2023 Financial Results and Corporate Update…

NEWS RELEASE 25 OCTOBER 2023, 4PM ET / 22:00 CETMDxHealth to Present Third Quarter 2023 Financial Resultsand Corporate Update on November 8 Company to Host Conference Call with Live Q&A, November 8, 2023 at 4:30pm ET/ 22:30 CETIRVINE, CA, and HERSTAL, BELGIUM– October 25, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH), a commercial-stage precision diagnostics company, today announced it will release its financial results for the third quarter and nine-month period ended...
Nasdaq GlobeNewswire
25/10/2023

Bavarian Nordic's Mpox Vaccine Receives Recommendation from U.S. CDC Advisory…

COPENHAGEN, Denmark, October 25, 2023– Bavarian Nordic A/S (OMX: BAVA) announced today that the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) has voted in favor of recommending the routine use of JYNNEOS ®, the Company's FDA-approved mpox vaccine, in adults at risk of mpox infection. Specifically, the ACIP voted to recommend that individuals 18 years and older with certain risk factors 1should receive the two-dose regimen of...
Nasdaq GlobeNewswire
25/10/2023

Groupe Casino: Opening of accelerated safeguard proceedings (procédures de…

Opening of accelerated safeguard proceedings ( procédures de sauvegarde accélérée ) and signature of conciliation protocols ( protocoles de conciliation ) Paris, 25 October 2023Casino Group announces the opening today of accelerated safeguard proceedings for the benefit of Casino, Guichard-Perrachon and certain of its subsidiaries 1in order to implement the restructuring plan of the Group in accordance with the terms of the lock-up agreement entered into on 5 October 2023 as...
Nasdaq GlobeNewswire
25/10/2023

Chandelier Market to Reach $22.9 Billion, Globally, by 2032 at 6.6% CAGR: Allied…

Request Sample Copy of Report: https://www.alliedmarketresearch.com/request-sample/157375 Request Sample Copy of Report:https://www.alliedmarketresearch.com/request-sample/157375 A chandelier is an elaborate lighting fixture characterized by multiple branches designed for ceiling or wall installation. Chandeliers frequently boast intricate designs and traditionally employ incandescent light bulbs, although contemporary versions may utilize fluorescent lamps or more recently, LEDs...
PR Newswire
25/10/2023

Valneva Submits Chikungunya Vaccine Marketing Application to EMA and Announces…

Saint-Herblain (France), October 25, 2023–Valneva SE(Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announces the submission of a marketing application with the European Medicines Agency (EMA) for approval of the Company's single-shot chikungunya vaccine candidate, VLA1553. Valneva was also granted accelerated assessment 1for the application by EMA's Committee for Medicinal Products for Human Use (CHMP) based on the vaccine candidate's “major interest for...
Nasdaq GlobeNewswire
25/10/2023

Ultimovacs Announces Webcast to Elaborate on the Results from Randomized UV1…

NON-REGULATORY PRESS RELEASEOslo, October 25, 2023 : Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, today announces that the Company will host a webcast presentation and discussion of the results from the NIPU study presented at the ESMO Congress 2023. The results from the randomized Phase II trial showed that Ultimovacs' cancer vaccine UV1, in combination with ipilimumab and nivolumab, demonstrated a...
Nasdaq GlobeNewswire
25/10/2023

Pre-Sterilized/Ready to Use Pharmaceutical Packaging Market Size to Expand…

The primary packaging of drugs and vaccines is important in ensuring their integrity, quality and protecting them from contaminants. Hence, sterilization is essential in pharmaceutical manufacturing because it helps maintain product safety and adhere to strict quality standards. This has increased the importance of pre-sterilized/ready-to-use containers in pharmaceutical packaging. Ready-to-use vials eliminate the need for in-house sterilization processes, reducing contamination risks and…
PR Newswire
25/10/2023

New Data from Biogen's Investigational Antisense Oligonucleotide (ASO) Targeting…

In the Phase 1b study, favorable trends were reported for the high-dose groups on multiple measures of cognition and function. First study of a tau targeting drug that shows reduction of aggregated tau pathology and favorable trends on clinical outcomes.Recruitment is underway for the Phase 2 CELIA study further investigating clinical efficacy and safety.CAMBRIDGE, Mass., Oct.25, 2023(GLOBE NEWSWIRE) --BiogenInc. (Nasdaq: BIIB) reported new Phase 1b clinical data from the...
Nasdaq GlobeNewswire
25/10/2023

Qilu Pharmaceutical announces the latest results from its clinical study on…

I. Research Background I. Research Background Currently, the preferred standard first-line treatment for r/mCC patients is cisplatin or carboplatin and paclitaxel plus bevacizumab, and efficacy and safety of the treatment also need to be considered. For r/mCC patients with positive PD-L1 expression, the PD-1 inhibitor pembrolizumab, administered with chemotherapy and with or without bevacizumab, is recommended as the standard first-line treatment. Immunotherapy combined with...
PR Newswire
25/10/2023

Cardiac Marker Testing Market Worth $6.9 billion | MarketsandMarkets

Cardiac Marker Testing Market in terms of revenue was estimated to be worth $4.4 billion in 2023 and is poised to reach $6.9 billion by 2028, growing at a CAGR of 9.4% from 2023 to 2028 according to a new report by MarketsandMarkets. The expansion of the cardiac marker testing market is propelled by several synergistic factors, including increasing demand for early diagnosis of cardiovascular diseases, escalating cardiovascular diseases prevalence, rising geriatric patient population, growing…
PR Newswire
25/10/2023

Oral Antibiotics Market to Reach $28.8 Billion, Globally, by 2032 at 2.5% CAGR…

Request Sample of the Report on Oral Antibiotics Market Forecast 2032- https://www.alliedmarketresearch.com/request-sample/6905 Request Sample of the Report on Oral Antibiotics Market Forecast 2032-https://www.alliedmarketresearch.com/request-sample/6905 Oral antibiotics are extensively employed to manage various bacterial infections, encompassing respiratory tract infections, urinary tract infections, skin and soft tissue infections, as well as gastrointestinal infections...
PR Newswire
25/10/2023
Altri  Comunicati